CDK Global Inc.

Practice Area: 
Stock Symbol: 
Case Status: 

Ademi LLP is investigating CDK Global (NASDAQ:CDK) for possible breaches of fiduciary duty and other violations of law in its transaction with Brookfield. 

Ademi LLP alleges CDK Global's financial outlook and prospects are excellent and yet CDK Global shareholders will receive only $54.87 per share in a transaction valued at approximately $8.3 billion. The transaction agreement unreasonably limits competing bids for CDK Global by prohibiting solicitation of further bids, and imposing a significant penalty if CDK Global accepts a superior bid. CDK Global insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of CDK Global's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for CDK Global.